Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amarantus, Anavex in Alzheimer's Biomarker Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Amarantus, Anavex in Alzheimer’s Biomarker Pact

Will use LymPro test to evaluate lead drug candidate combination

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amarantus BioScience and Anavex Life Sciences Corp. have entered a biomarker services agreement under which Amarantus will evaluate the pharmacodynamic effect of a lead drug candidate combination on the expression of the biomarker CD69 using its Alzheimer’s blood diagnostic LymPro Test.
 
The drugs, ANAVEX 2-73 and ANAVEX PLUS, which combines ANAVEX 2-73 with donepezil (Aricept), are Anavex’ lead drug candidate and drug candidate combination, respectively, for Alzheimer’s disease.
 
Additionally, the companies have entered into a Letter of Intent for Amarantus to assist Anavex in planning the blood-based biomarker components of Anavex’ next Phase III trial in Alzheimer’s patients. Initial data from Anavex’ Phase IIa trial is expected in 3Q15.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics